A Phase III double blind-blind randomized , placebo controlled study to evaluate the safety , reactogenicity and immune response of a single intramuscular dose of unadjuvanted RSV maternal vaccine in high risk pregnant women aged 15 to 49 years and infants born to the vaccinated mothers.